Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00819637 · ClinicalTrials.gov registry record · Phase 4
A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients
A Phase 4 study, sponsored by Henry Ford Health System.
- Terminated
- Registry status
- Phase 4
- Development phase
- 2
- Enrollment target
NCT00819637 is a Phase 4 study that was terminated before completion, run by Henry Ford Health System. The registered enrollment target is 2 participants.
The verdict
NCT00819637, a Phase 4 study, was terminated before completion, sponsored by Henry Ford Health System.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 2 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the best dose of nebulized arformoterol, a quick onset but long acting beta agonist, for use in treating acute bronchospasm in asthmatics presenting to the the Emergency Department. Also this study will evaluate the side effect and safety profile of arformoterol when used in this situation.
Interventions
- DRUG placebo
- DRUG levalbuterol
- DRUG arformoterol (RR formoterol)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2 participants |
| Start Date | 2009-01 |
| Est. Completion | 2009-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00819637
The ClinicalTrials.gov registry entry for NCT00819637 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 2 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Henry Ford Health System, which has 234 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which placebo is the first listed.
NCT00819637 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00819637 about?
NCT00819637 is a clinical study titled "A Pilot Study to Determine the Most Effective Dose of Arformoterol for Treating Acute Asthmatic Patients". The purpose of this study is to determine the best dose of nebulized arformoterol, a quick onset but long acting beta agonist, for use in treating acute bronchospasm in asthmatics presenting to the the Emergency Department. Also this study will evaluate the side effect and safety profile of arformot...
What is the current status of trial NCT00819637?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 2 participants. The study started on 2009-01. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00819637?
The interventions under investigation include: placebo (DRUG), levalbuterol (DRUG), arformoterol (RR formoterol) (DRUG).
Who is sponsoring clinical trial NCT00819637?
This trial is sponsored by Henry Ford Health System, which has 234 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.